What Actually Happens
Picture this: you're lying in a medical chair, monitoring equipment quietly beeping, as a small dose of ketamine enters your bloodstream. Within minutes, the familiar weight of depression begins to lift, replaced by a dreamlike state where thoughts flow differently. A trained therapist sits nearby, offering gentle guidance as your mind explores territories usually blocked by rigid thought patterns.
This is ketamine-assisted psychotherapy (KAP) — not the recreational drug use you might have heard about, but a structured medical treatment that pairs sub-anaesthetic ketamine with professional psychotherapy. The ketamine creates a window of neuroplasticity and reduced psychological defences, while the therapist helps you process what emerges.
Unlike traditional antidepressants that require weeks to take effect, people often notice shifts within hours or days. The therapy component distinguishes this from ketamine infusion alone, aiming to turn temporary neurochemical changes into lasting psychological insights.
From Anaesthetic to Antidepressant
Ketamine was synthesised in 1962 as an anaesthetic — and it's still used in operating theatres today. But in the 1990s, researchers noticed something unexpected: patients receiving ketamine showed rapid improvement in depression, even those who'd failed multiple treatments.
This led to decades of research exploring ketamine's unique mechanism. Unlike conventional antidepressants that target serotonin, ketamine blocks NMDA receptors in the brain, triggering a cascade of changes that promote new neural connections. The psychotherapy component evolved from observations that people often had profound psychological experiences during ketamine sessions — experiences that needed processing to create lasting change.
The first ketamine-based medication (Spravato, an intranasal form) received approval from the Medicines and Healthcare products Regulatory Agency in 2019 for treatment-resistant depression, though this was for medication-only protocols rather than the psychotherapy-integrated approach.
How Mind and Medicine Interact
KAP operates on multiple levels simultaneously. Ketamine rapidly increases levels of BDNF (brain-derived neurotrophic factor), essentially creating new neural pathways within hours. This neuroplasticity makes the brain temporarily more malleable — like heated metal that can be reshaped.
The psychological mechanism involves what researchers call 'cognitive flexibility.' Depression often involves rigid, negative thought patterns that feel impossible to escape. Ketamine appears to loosen these patterns, allowing people to experience their thoughts and emotions from new perspectives.
Many people describe insights that feel obvious in retrospect but were previously inaccessible. A person might suddenly understand how childhood experiences shaped their adult relationships, or feel genuine self-compassion for the first time. The therapist's role is crucial here — helping integrate these experiences into practical changes rather than letting them fade as the ketamine wears off.
The Three-Phase Process
KAP follows a structured protocol beginning with preparation sessions. Your therapist will explore your history, establish rapport, and help set intentions for the ketamine experiences. This isn't just form-filling — the quality of therapeutic relationship significantly affects outcomes.
During medicine sessions, ketamine is administered via IV, intramuscular injection, or sublingual tablets, depending on your practitioner's protocol. You'll typically experience a dissociative state lasting 45-90 minutes, often described as dreamy or otherworldly. The therapist remains present, offering gentle support but allowing your mind to wander freely.
Integration sessions follow within days, processing whatever arose during the ketamine experience. These might reveal patterns, memories, or emotions that need ongoing therapeutic work. Most protocols involve 6-12 sessions over several months, with maintenance sessions as needed.
Current Evidence and Limitations
Early research is promising but remains preliminary. A 2021 systematic review found that 60-70% of people with treatment-resistant depression showed significant improvement with ketamine-assisted psychotherapy, compared to roughly 30% with conventional treatments.
However, most studies involve small samples (20-100 participants) with short follow-up periods. The largest controlled trial to date included just 233 participants, and we lack data on long-term outcomes beyond one year. Publication bias is also a concern — negative results may be under-reported in this emerging field.
Perhaps most importantly, we don't yet know who responds best to KAP. Some people experience dramatic, lasting improvements after just a few sessions. Others see temporary relief that requires ongoing maintenance. A minority don't respond at all, and we can't reliably predict which group someone will fall into.
Finding Qualified Care
KAP requires two types of expertise: medical supervision for ketamine administration and psychotherapy training for integration work. Look for practitioners with specific KAP training from recognised organisations like the Ketamine Assisted Psychotherapy Association or similar bodies.
Medical providers should be psychiatrists, anaesthetists, or other physicians with ketamine experience. Therapists should be registered with professional bodies like UKCP or BACP with additional KAP certification. Some clinics employ teams where medical and therapy roles are separated.
Expect to pay £300-800 per session, with most protocols requiring 6-12 sessions initially. This isn't currently available through the NHS, though some private insurance plans may offer coverage. Treatment typically requires several months of commitment, both financially and emotionally.
Before beginning, ensure your provider conducts thorough medical and psychiatric screening, maintains emergency protocols for adverse reactions, and offers clear integration support between sessions.
